Vyuhpharma

Highlights from the week of
06th July - 13th July

Sanofi

(FDA, Approval)

FDA approves Sanofi's Sarclisa Escena SC in combination with SOC regimens to treat multiple myeloma

---

Pfizer

(FDA, Approval)

Pfizer gets FDA approval for PADCEV plus KEYTRUDA or KEYTRUDA QLEX as neoadjuvant and adjuvant treatment for adults with MIBC regardless of cisplatin eligibility

---

Accord BioPharma

(FDA, Approval)

Accord BioPharma obtains FDA approval of ENNUMO for adults and pediatrics to treat the same indications as NEULASTA biosimilar

---

Vera Therapeutics

(FDA, Accelerated Approval)

FDA gives accelerated approval to Vera Therapeutics' TRUTAKNA that treats proteinuria in adults with primary IgAN

Vyuhpharma

Highlights from the week of
06th July - 13th July

Genmab

(EU, Approval)

EC grants approval to Genmab's TEPKINLY in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma

---

Arialys

(FDA, Fast Track)

FDA grants Fast Track designation to Arialys' ART5803 to treat anti-NMDA receptor encephalitis

---

Merck

(FDA, Breakthrough Therapy)

Merck gains FDA Breakthrough Therapy designation for enpatoran, to treat lupus with active cutaneous manifestations

---

Agios

(FDA, Priority Review)

FDA provides Priority Review to Agios' mitapivat sNDA to treat sickle cell disease, with a PDUFA date of November 1, 2026

Vyuhpharma

Highlights from the week of
06th July - 13th July

Tarsus Pharmaceuticals *(Acquisition)*

Tarsus acquires iRenix Medical, including its IRX-101, an ocular antiseptic, for an upfront payment of approximately $75M

Incyte *(Acquisition)*

Incyte acquires Vega Therapeutics including VGA039, a strong strategic fit to its hematology portfolio that treats von Willebrand disease, with an upfront payment of $1.25B

Biocytogen *(Collaboration)*

Biocytogen and Whitehawk Therapeutics enter a global collaboration to develop BsADCs using Biocytogen's proprietary RENLITE platform

Astex Pharmaceuticals *(Collaboration)*

Astex Pharmaceuticals collaborates with Genentech to identify small molecule candidates with selective inhibitory activity as potential treatments for breast cancer, for an upfront payment of $25M

Vyuhpharma

Highlights from the week of
06th July - 13th July

Teva

(Collaboration)

Teva collaborates with Polpharma Biologics to commercialize OCREVUS IV and SC formulations, expanding its biosimilar pipeline

---

Ipsen

(Phase 3, Results)

Ipsen's Phase 3 BEOND migraine program evaluating DYSPORT met its primary endpoint, with reduction in monthly migraine days compared to placebo, with significant efficacy in episodic migraine

---